470 related articles for article (PubMed ID: 7905543)
21. Alterations in the K-ras and p53 genes in rat lung tumors.
Belinsky SA; Swafford DS; Finch GL; Mitchell CE; Kelly G; Hahn FF; Anderson MW; Nikula KJ
Environ Health Perspect; 1997 Jun; 105 Suppl 4(Suppl 4):901-6. PubMed ID: 9255578
[TBL] [Abstract][Full Text] [Related]
22. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene.
Evers BM; Rady PL; Sandoval K; Arany I; Tyring SK; Sanchez RL; Nealon WH; Townsend CM; Thompson JC
Ann Surg; 1994 Jun; 219(6):596-601; discussion 602-4. PubMed ID: 7911296
[TBL] [Abstract][Full Text] [Related]
23. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
24. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.
Li ZH; Zheng J; Weiss LM; Shibata D
Am J Pathol; 1994 Feb; 144(2):303-9. PubMed ID: 8311114
[TBL] [Abstract][Full Text] [Related]
25. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung.
Westra WH; Slebos RJ; Offerhaus GJ; Goodman SN; Evers SG; Kensler TW; Askin FB; Rodenhuis S; Hruban RH
Cancer; 1993 Jul; 72(2):432-8. PubMed ID: 8319174
[TBL] [Abstract][Full Text] [Related]
26. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
27. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Goodrow T; Reynolds S; Maronpot R; Anderson M
Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119
[TBL] [Abstract][Full Text] [Related]
28. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
29. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
30. p53 and K-ras in radon-associated lung adenocarcinoma.
McDonald JW; Taylor JA; Watson MA; Saccomanno G; Devereux TR
Cancer Epidemiol Biomarkers Prev; 1995; 4(7):791-3. PubMed ID: 8672998
[TBL] [Abstract][Full Text] [Related]
31. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
32. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.
Rodenhuis S; van de Wetering ML; Mooi WJ; Evers SG; van Zandwijk N; Bos JL
N Engl J Med; 1987 Oct; 317(15):929-35. PubMed ID: 3041218
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
[TBL] [Abstract][Full Text] [Related]
34. Low frequency of alterations in p53, K-ras, and mdm2 in rat lung neoplasms induced by diesel exhaust or carbon black.
Swafford DS; Nikula KJ; Mitchell CE; Belinsky SA
Carcinogenesis; 1995 May; 16(5):1215-21. PubMed ID: 7539340
[TBL] [Abstract][Full Text] [Related]
35. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
36. Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.
Candrian U; You M; Goodrow T; Maronpot RR; Reynolds SH; Anderson MW
Cancer Res; 1991 Feb; 51(4):1148-53. PubMed ID: 1997158
[TBL] [Abstract][Full Text] [Related]
37. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
Rodenhuis S; Slebos RJ; Boot AJ; Evers SG; Mooi WJ; Wagenaar SS; van Bodegom PC; Bos JL
Cancer Res; 1988 Oct; 48(20):5738-41. PubMed ID: 3048648
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
39. Expression of biomarkers (p53, transforming growth factor alpha, epidermal growth factor receptor, c-erbB-2/neu and the proliferative cell nuclear antigen) in oropharyngeal squamous cell carcinomas.
Ibrahim SO; Lillehaug JR; Johannessen AC; Liavaag PG; Nilsen R; Vasstrand EN
Oral Oncol; 1999 May; 35(3):302-13. PubMed ID: 10621852
[TBL] [Abstract][Full Text] [Related]
40. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Volm M; Efferth T; Mattern J
Anticancer Res; 1992; 12(1):11-20. PubMed ID: 1348920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
